EYE-SYNC Platform Becomes Official Concussion Management Technology of the XFL
ARLINGTON, TX, PALO ALTO, CA and BOSTON, MA – May 4, 2023 – The XFL and NeuroSync today announced a partnership that establishes NeuroSync’s award-winning EYE-SYNC technology as the Official and Exclusive Concussion Management Technology of the XFL. Since the launch of the season, the XFL has relied on the objective data and unique insights provided by EYE-SYNC to support the concussion diagnostic decision-making process, and to ensure a safe return to play.
“Having a market-leading clinical solution like EYE-SYNC at our disposal has armed our medical personnel with objective, quantifiable data enabling us to make better decisions about the status of our players and ultimately improve their care and clinical outcomes,” said Kerry Gordon, VP of Health and Safety. “Our medical providers and players have worked with the team at NeuroSync to deliver a best-in-class, comprehensive concussion management protocol.”
As the first professional sports organization to uniformly adopt and comprehensively implement EYE-SYNC as a leaguewide solution, we are honored to partner with the XFL,” said NeuroSync Chairman and CEO Gary Gregory. “Their technology-driven, data-centric approach to player safety and development is a perfect match for our game changing technology, and we look forward to advancing concussion care in professional football through our work together.”
In addition to EYE-SYNC’s role on gameday, the XFL has also utilized the technology to better understand the type and severity of concussion injury, leading to a more specific treatment and recovery plan. NeuroSync has worked collaboratively with the XFL to conduct player preseason baseline screenings, assess relevant player and position-specific injury data, conduct extensive injury-related analysis on prevalence and recovery timelines, and make recommendations to improve player health and safety.
The EYE-SYNC technology combines proprietary software and data analytics with high-performance sensors in a Virtual Reality (VR) headset to measure and quantify eye movement abnormalities that often occur after a concussion. FDA-cleared as an aid to concussion diagnosis, EYE-SYNC is the only VR technology approved by the FDA for neurological care. It is currently used by healthcare providers in hospitals and rehabilitation centers, sports, military, and in CNS drug development around the world.
We are excited about our collaboration to date and for the opportunity to positively impact the concussion diagnostic workflow at the XFL to advance how players are cared for after injury,” said NeuroSync Chief Clinical Officer Scott Anderson. “Emerging evidence continues to underscore the value of tailoring treatments to specific impairments, and the rich data provided by EYE-SYNC will do exactly that – allowing providers and players to objectively diagnose conditions and gauge improvement over time to know when it is safe to resume activity.”
Up-to-date league, team and player information is now available on Twitter from the XFL communications department at @XFL_PR.
For more information, visit XFL.com and follow us on Twitter, Facebook, and Instagram.
To learn more about NeuroSync, please visit neurosync.health.
The XFL is a fan-first, fast-paced global professional football league with innovative rules and an enhanced 360-degree game experience. Anchored in world-class football, the XFL brings entertainment and innovation to advance the sport, expand player opportunities, and change the way that fans experience the game. The XFL has eight teams in Arlington (TX), Houston (TX), Las Vegas (NV), Orlando (FL), San Antonio (TX), Seattle (WA), St. Louis (MO), and Washington D.C.. The XFL is owned by Dany Garcia, Dwayne Johnson, and Gerry Cardinale’s RedBird Capital Partners and launched in February 2023.
About NeuroSync, Inc
Named one of SBJ’s Top 10 Most Innovative Sports Tech Companies in 2023, NeuroSync is on a mission to provide objective neurological measurements that assist medical and performance professionals by assessing brain health conditions, delivering therapies, and enhancing cognitive function. Harnessing the power of AI, NeuroSync develops revolutionary eye-tracking software and analytic technologies, delivered in a rapid, accurate, and easy to use XR platform. Backed by more than 30 peer-reviewed publications and 16 patents, NeuroSync products include customizable assessment workflows, dynamically immersive therapeutics, and multisensory training environments. Trusted by over 4,000 providers at leading medical centers from Stanford to Massachusetts General and more than 30 organizations across professional and collegiate sport, NeuroSync is transforming neurological care across the lifespan of patients and athletes.